299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00843817 (ClinicalTrials.gov)	April 2009	12/2/2009	RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum	RhDNase Effect on Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum	Cystic Fibrosis	Drug: Pulmozyme	University Hospital, Tours	NULL	Completed	18 Years	N/A	All	15	Phase 4	France
2	NCT00557089 (ClinicalTrials.gov)	January 2008	9/11/2007	The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis	Randomized, Placebo-controlled Trial on the Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: rhDNAse;Other: Placebo	The Hospital for Sick Children	NULL	Completed	6 Years	18 Years	Both	17	Phase 4	Canada
3	NCT00117208 (ClinicalTrials.gov)	November 2005	30/6/2005	Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis	A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis	Cystic Fibrosis	Drug: mannitol;Drug: mannitol + pulmozyme;Drug: Dornase alpha	Pharmaxis	NULL	Completed	8 Years	18 Years	Both	20	Phase 2	United Kingdom
4	EUCTR2004-001888-21-GB (EUCTR)	03/12/2004	22/02/2005	A cross-over comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis - Inhaled Mannitol in Cystic Fibrosis	A cross-over comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis - Inhaled Mannitol in Cystic Fibrosis	Cystic fibrosis (CF)	Product Name: DP Mannitol INN or Proposed INN: Mannitol Trade Name: Pulmozyme (dornase alfa) Product Name: Pulmozyme (dornase alfa) INN or Proposed INN: Dornase alfa Other descriptive name: rhDNAse	Pharmaxis Ltd	NULL	Not Recruiting			Female: yes Male: yes	42	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
5	EUCTR2007-001548-36-DE (EUCTR)		27/07/2009	Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cf	Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cf	Cystic Fibrosis with chronic rhinosinusitis	Trade Name: Pulmozyme Product Name: Pulmozyme INN or Proposed INN: Dornase alfa Other descriptive name: recombiant human Desoxyribonuclease ( rhDNase)	University of Jena	NULL	Not Recruiting			Female: yes Male: yes	16	Phase 3	Germany
6	EUCTR2007-000935-25-NL (EUCTR)		02/04/2007	‘Peripheral targeting of inhaled rhDNase in stable CF patients.’	‘Peripheral targeting of inhaled rhDNase in stable CF patients.’	Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis MedDRA version: 9.1;Classification code 10011763;Term: Cystic fibrosis lung	Trade Name: Pulmozyme (Dornase alpha) Product Name: Pulmozyme	ErasmusMC - Sophia Children's Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		Netherlands